Genetic Mechanism Augments DHT Synthesis in CRPC


Nima Sharifi, MD


What is it? What does it do?

The technology is a diagnostic tool that assesses an actionable biomarker for treatment selection in the prostate cancer care continuum.  Growth of prostate cancer cells is dependent upon stimulation of the androgen receptor (AR) by dihydrotestosterone (DHT).  Dr. Nima Sharifi has discovered that Castration Resistant Prostate Cancer (CRPC) sometimes expresses a mutation that catalyzes the initial rate-limiting step in hormone conversion and provides the hormone necessary to activate the AR to promote continued tumor propagation. This in turn causes the patient to become resistant to androgen-deprivation therapies.

Why is it better?

  • First-in-market biomarker assays that support tailored treatment in CRPC
  • Enables patient stratification for clinical trial selection and choosing right therapy across prostate cancer care continuum

What is its current status?

A prototype assay for the determination of mutation status of the 3β-HSD1 gene has been developed and utilized to correlate that inheritance of the 3β-HSD1 mutant/variant profoundly hastens the development of CRPC and death from CRPC by supplying the machinery for abundant DHT synthesis.

IP Status





Other Technologies by Inventor

Other Technologies by Innovation Manager

Get in Touch With Us